A prospective, observational safety study of patients with BRAFV 600 -mutated unresectable or metastatic melanoma treated with vemurafenib [Zelboraf Safety Study (ZeSS)].

Related Articles

A prospective, observational safety study of patients with BRAFV 600 -mutated unresectable or metastatic melanoma treated with vemurafenib [Zelboraf Safety Study (ZeSS)].

Br J Dermatol. 2018 Nov 29;:

Authors: Corrie PG, Terheyden P, Ten Tije AJ, Herbst R, Jansen R, Marples M, Debus D, Marconcini R, Blasinska-Morawiec M, Freivogel K, Munson MLG, Goodman GR, Hsu JJ, Sadetsky N, Colburn D, Rutkowski P

Abstract
Vemurafenib is approved in more than 90 countries for the treatment of patients with BRAFV 600 -mutated metastatic melanoma.1,2 In the pivotal BRIM-3 trial, treatment-emergent cutaneous side effects were associated with vemurafenib, including the development of epithelial tumours and, in rare cases, new primary melanomas.3,4 QTc interval prolongation and hepatic laboratory abnormalities were also noted.3,4 This article is protected by copyright. All rights reserved.

PMID: 30488430 [PubMed - as supplied by publisher]

from PubMed via alexandrossfakianakis on Inoreader https://ift.tt/2zAbhQp